CRD-740 not checked

Cardurion Pharmaceuticals, Inc.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Heart Failure (2 trials), Cardiovascular Diseases (2 trials), Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Heart Diseases, Clinical Pharmacology, Pharmacokinetics
Main trialPhase 2
“This is a study evaluating the effectiveness of CRD-740 in patients with either Heart Failure with Reduced Ejection Fraction (HFrEF) or Heart Failure with Preserved Ejection Fraction (HFpEF) after 12 weeks of treatment. The primary objective in Part A is to assess the effect of CRD-740 compared to placebo in plasma cGMP at Week 4 in HFrEF. Part B of the study was not conducted in favor of redesigned new studies.”In the company’s words, NCT05409183 on ClinicalTrials.gov

Other drugs for Heart Failure

All 42 drugs for Heart Failure

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Terminated 2 May 2023 Effectiveness of CRD-740 in Heart Failure
Phase 1Completed 3 Aug 2022 Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow CRD-740

Following is part of Solo: you see every change to CRD-740 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in